Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy

Frederik Persson; Julia B Lewis; Edmund J Lewis; Peter Rossing; Norman K Hollenberg; Hans-Henrik Parving; AVOID Study Investigators

doi:10.2337/dc10-0833

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy

Frederik Persson, Julia B Lewis, Edmund J Lewis, Peter Rossing, Norman K Hollenberg, Hans-Henrik Parving, AVOID Study Investigators

60 Citations (Scopus)

Abstract

Proteinuric diabetic patients with reduced glomerular filtration rate (GFR) are at high risk of renal and cardiovascular disease progression and treatment-related adverse events. This post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1-3 chronic kidney disease [CKD]).

Original language	English
Journal	Diabetes Care
Volume	33
Issue number	11
Pages (from-to)	2304-9
Number of pages	6
ISSN	0149-5992
DOIs	https://doi.org/10.2337/dc10-0833
Publication status	Published - 1 Nov 2010

Access to Document

10.2337/dc10-0833

Cite this

@article{277ada2009874e83a80a39e9715750c7,

title = "Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy",

abstract = "Proteinuric diabetic patients with reduced glomerular filtration rate (GFR) are at high risk of renal and cardiovascular disease progression and treatment-related adverse events. This post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1-3 chronic kidney disease [CKD]).",

author = "Frederik Persson and Lewis, \{Julia B\} and Lewis, \{Edmund J\} and Peter Rossing and Hollenberg, \{Norman K\} and Hans-Henrik Parving and \{AVOID Study Investigators\}",

year = "2010",

month = nov,

day = "1",

doi = "10.2337/dc10-0833",

language = "English",

volume = "33",

pages = "2304--9",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association",

number = "11",

}

TY - JOUR

T1 - Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy

AU - Persson, Frederik

AU - Lewis, Julia B

AU - Lewis, Edmund J

AU - Rossing, Peter

AU - Hollenberg, Norman K

AU - Parving, Hans-Henrik

AU - AVOID Study Investigators

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Proteinuric diabetic patients with reduced glomerular filtration rate (GFR) are at high risk of renal and cardiovascular disease progression and treatment-related adverse events. This post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1-3 chronic kidney disease [CKD]).

AB - Proteinuric diabetic patients with reduced glomerular filtration rate (GFR) are at high risk of renal and cardiovascular disease progression and treatment-related adverse events. This post hoc analysis assessed the efficacy and safety of aliskiren added to the maximal recommended dose of losartan according to baseline estimated GFR (eGFR) (stage 1-3 chronic kidney disease [CKD]).

UR - https://www.scopus.com/pages/publications/78649929199

U2 - 10.2337/dc10-0833

DO - 10.2337/dc10-0833

M3 - Journal article

C2 - 20693353

SN - 0149-5992

VL - 33

SP - 2304

EP - 2309

JO - Diabetes Care

JF - Diabetes Care

IS - 11

ER -

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this